182 related articles for article (PubMed ID: 21984119)
21. Price comparison of high-cost originator medicines in European countries.
Vogler S; Zimmermann N; Babar ZU
Expert Rev Pharmacoecon Outcomes Res; 2017 Apr; 17(2):221-230. PubMed ID: 27658050
[TBL] [Abstract][Full Text] [Related]
22. Does the market share of generic medicines influence the price level?: a European analysis.
Dylst P; Simoens S
Pharmacoeconomics; 2011 Oct; 29(10):875-82. PubMed ID: 21797288
[TBL] [Abstract][Full Text] [Related]
23. Market Integration and Price Dynamics under Market Shocks in European Union Internal and External Cheese Export Markets.
Xue H; Wang L; Li C
Foods; 2022 Feb; 11(5):. PubMed ID: 35267325
[TBL] [Abstract][Full Text] [Related]
24. Projecting Pharmaceutical Expenditure in EU5 to 2021: Adjusting for the Impact of Discounts and Rebates.
Espin J; Schlander M; Godman B; Anderson P; Mestre-Ferrandiz J; Borget I; Hutchings A; Flostrand S; Parnaby A; Jommi C
Appl Health Econ Health Policy; 2018 Dec; 16(6):803-817. PubMed ID: 30088251
[TBL] [Abstract][Full Text] [Related]
25. The drug market in four European countries.
Garattini S
Pharmacoeconomics; 1998; 14 Suppl 1():69-79. PubMed ID: 10186484
[TBL] [Abstract][Full Text] [Related]
26. OSTEOPOROSIS DRUGS MARKETED IN THE UNITED STATES: GENERIC COMPETITION, PRICING STRUCTURE, AND DISPERSION AMONG PAYERS.
Balkhi B; Seoane-Vazquez E; Rodriguez-Monguio R
Int J Technol Assess Health Care; 2016 Jan; 32(6):385-392. PubMed ID: 28065194
[TBL] [Abstract][Full Text] [Related]
27. [The new reference prices: an opportunity for efficient management of medication].
Ausejo Segura M
Aten Primaria; 2005 Feb; 35(2):64-6. PubMed ID: 15727746
[No Abstract] [Full Text] [Related]
28. Price regulation and generic competition in the pharmaceutical market.
Dalen DM; Strøm S; Haabeth T
Eur J Health Econ; 2006 Sep; 7(3):208-14. PubMed ID: 16841230
[TBL] [Abstract][Full Text] [Related]
29. Impacts of regulated competition on pricing in Chinese pharmaceutical market under urban employee basic medical insurance.
Zhao M; Wu J
Expert Rev Pharmacoecon Outcomes Res; 2017 Jun; 17(3):311-320. PubMed ID: 27762144
[TBL] [Abstract][Full Text] [Related]
30. Comparison of US and EU Prices for Orphan Drugs in the Perspective of the Considered US Orphan Drugs Act Modifications and Discussed Price-Regulation Mechanisms Adjustments in US and European Union.
Żelewski P; Wojna M; Sygit K; Cipora E; Gąska I; Niemiec M; Kaczmarski M; Banaś T; Karakiewicz B; Kotwas A; Zabielska P; Partyka O; Pajewska M; Krzych-Fałta E; Bandurska E; Ciećko W; Czerw A
Int J Environ Res Public Health; 2022 Sep; 19(19):. PubMed ID: 36231399
[TBL] [Abstract][Full Text] [Related]
31. Do pharmaceutical prices respond to potential patient out-of-pocket expenses?
Pavenik N
Rand J Econ; 2002; 33(3):469-87. PubMed ID: 12585303
[TBL] [Abstract][Full Text] [Related]
32. What future does the pharmaceutical industry have in the cardiovascular world?
Braunwald E
Eur Heart J; 2013 Apr; 34(13):943-4. PubMed ID: 23546415
[No Abstract] [Full Text] [Related]
33. Comparative approaches to pharmaceutical price regulation in the European Union.
Mrazek MF
Croat Med J; 2002 Aug; 43(4):453-61. PubMed ID: 12187524
[TBL] [Abstract][Full Text] [Related]
34. Implication of external price referencing and parallel trade on pharmaceutical expenditure: indirect evidence from lower-income European countries.
Elek P; Takács E; Merész G; Kaló Z
Health Policy Plan; 2017 Apr; 32(3):349-358. PubMed ID: 27697777
[TBL] [Abstract][Full Text] [Related]
35. Sanofi vows to limit price hikes- but will it make much difference?
Kacik A
Mod Healthc; 2017 May; 47(20):12. PubMed ID: 30496647
[TBL] [Abstract][Full Text] [Related]
36. Prices and distribution margins of in-patent drugs in pharmacy: a comparison in seven European countries.
Garattini L; Motterlini N; Cornago D
Health Policy; 2008 Mar; 85(3):305-13. PubMed ID: 17928092
[TBL] [Abstract][Full Text] [Related]
37. The impact of generic substitution on price competition in Finland.
Aalto-Setälä V
Eur J Health Econ; 2008 May; 9(2):185-91. PubMed ID: 17508226
[TBL] [Abstract][Full Text] [Related]
38. Projected economic impact of clinical findings of generic entry of topiramate on G4 European countries.
Paradis PE; Latrémouille-Viau D; Moore Y; Mishagina N; Lafeuille MH; Lefebvre P; Gaudig M; Duh MS
Curr Med Res Opin; 2009 Jul; 25(7):1793-805. PubMed ID: 19505202
[TBL] [Abstract][Full Text] [Related]
39. Biosimilar versus patented erythropoietins: learning from 5 years of European and Japanese experience.
Bocquet F; Paubel P; Fusier I; Cordonnier AL; Sinègre M; Le Pen C
Appl Health Econ Health Policy; 2015 Feb; 13(1):47-59. PubMed ID: 25189295
[TBL] [Abstract][Full Text] [Related]
40. [Competition between branded and generic drugs in Austria: evidence from the market for ACE inhibitors].
Mahlich JC; Stadler I
Gesundheitswesen; 2012 Jan; 74(1):23-8. PubMed ID: 21154203
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
